Introduction 59
The development of a safe recombinant hepatitis B vaccine has led to the inclusion 60 of hepatitis B vaccination in the national infant immunization schedules of 61 approximately 160 countries [1] . Recombinant DNA technology was used to produce 62 hepatitis B surface antigen (HBsAg) in form of virus-like particles (VLPs) using the 63 yeast Saccharomyces cerevisiae leading to the development of a so-called "second" 64 generation hepatitis B vaccine and the first recombinant subunit vaccine available 65
[2]. This formulation of the hepatitis B vaccine has been on the market since 1986. 66
Initially, HBsAg VLPs of ~22 nm were purified from the plasma of asymptomatic 67 HBV carriers, but due to safety issues and restricted supply, the "first" generation 68 plasma-derived vaccines are no longer in use [2] . Nowadays, as patents have expired, 69 "third" generation "biosimilar" recombinant HBsAg VLP-based vaccines are being 70 introduced into the market by a variety of new manufacturers which try to make the 71 vaccine also more affordable to developing countries [2] . 72
As HBsAg is a very hydrophobic protein, secretion is inefficient in yeast and 73 high-level production has been only achieved as intracellular product. The 74 purification of recombinant HBsAg from yeast cultures is well documented , 75 [see Tables 1 and 2] and several studies have shown that purified yeast-derived 76
HBsAg can assemble into characteristic ~22 nm VLPs [26] [27] [28] [29] . These particles are 77 highly immunogenic and capable of eliciting potent neutralizing antibodies as they 78 mimic the conformation of native viruses but lack the viral genome and can be used 79 as safe and cheap vaccine [26, [30] [31] [32] . 80
Previously, we have reported a simple fed-batch technique which leads to the 81 production of ~6-7 g/l HBsAg, with 30% in a "soluble" form competent for assembly 82 into VLPs [29] . Although, the purification of HBsAg VLPs was reported before in 83 thermomixer. In pilot scale studies, cell lysis was essentially carried out as described 117 previously [24] . The washed cell pellet from 1 liter culture broth was resuspended in 118 1 liter ice-cold lysis buffer [25 mM phosphate buffer, pH 8.0, 5 mM EDTA, 0.6% 119 (v/v) Tween-20] and the pre-cooled cell suspension disrupted by high pressure 120 homogenization (Gaulin Lab 60, APV Gaulin, Germany) using four cycles at 600 bar 121 and ~4°C. Cell lysis was confirmed by microscopy. 122 123
Step 2: Polyethylene glycol (PEG) precipitation 124
To the lysate collected after high pressure homogenization, a 5 M NaCl solution was 125 slowly added within 30 min to a final concentration of 500 mM followed by the 126 addition of polyethylene glycol 6000 (S. D. Fine-Chem, India, 50% w/v) to a final 127 concentration of 5% (w/v). This suspension was stirred for 2 h at 4°C and 128 precipitation was then allowed to occur for 12-16 h at 4°C without stirring. The 129 suspension was then clarified by centrifugation at 4°C and 4,225 g for 15 min. 130 131
Step 3: Aerosil-380 adsorption 132
Prior to use, Aerosil-380 (Evonik, Hanau, Germany) was pre-equilibrated, e.g. 133 washed twice, with 25 mM sodium phosphate buffer, pH 7.2, 500 mM NaCl 134 (centrifuged at 4,225 g for 15 min and 4°C). The clarified supernatant obtained after 135 PEG precipitation (removal of host cell proteins and other host contaminants) was 136 mixed with Aerosil-380 (0.13 g of dry Aerosil-380 pre-equilibrated per g initial wet 137 cell mass). This suspension was stirred for 4 h at 4°C and centrifuged at 4°C and 138 4,225 g for 15 min. The pellet (corresponding to 1 liter of initial culture broth) was 139 washed twice with 25 mM phosphate buffer (pH 7.2), centrifuged as above, finally 140 resuspended in 800 ml of 50 mM sodium carbonate-bi-carbonate buffer, pH 10. 
Detection of antigen-specific IgG in the sera 223
The HBsAg VLP-specific antibodies were determined in the serum samples by 224 ELISA using microtitre plates coated with 100 µ l/well of the respective antigen (2 225 µg/ml in 0.05 M carbonate buffer, pH 9.6, as previously described [37] . 226 227
Measurement of cellular proliferation 228
The spleens of vaccinated mice were aseptically removed, single-cell suspensions 229 were prepared and the erythrocytes lysed by 2 min incubation in ACK buffer. The 230 cells were washed twice and adjusted to 2 x 10 6 cells/ml in complete RPMI medium 231 containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. clarified PEG extracts at neutral pH through hydrophobic adsorption. Elution of 296 bound HBsAg from silica using 50 mM sodium carbonate-bicarbonate buffer, pH 297 10.5, resulted in an unsatisfactory recovery. However, the recovery increased ~10-298 fold by supplementing the elution buffer with 1.2 M urea leading to an HBsAg eluate 299 with a purity of 60-70% (Table 3 ). The following ion exchange chromatography step 300 (Figure 2A ) further increased the purity of HBsAg to 90-95% (Table 3, Figure 2B) . and KSCN. In total, approx. 50 mg HBsAg VLPs with a purity of >99% can be 321 recovered from one liter culture broth with a final yield of around 3% (Tables 2 and  322 3). The entire HBsAg production and purification process is outlined in Figure 4 . 323 324
In vitro characterization of purified HBsAg 325
The final bulk protein was also analyzed by RP-HPLC and compared with the 326 NIBSC standard (code number -00/588). A retention time of 10.9 min was observed 327 as was found for the standard (data not shown). The HBsAg did not show any 328 binding to lectins, thus proving absence of glycosylation (data not shown). Finally, 329 electron microscopy of pure HBsAg, obtained using either ultracentrifugation or 330 size-exclusion chromatography, revealed in both cases the presence of the 331 characteristic icosahedral symmetrical structures with a diameter of ~22 nm, the so-332 called HBsAg "VLPs" (included in Figure 3) . 333 
